Francis Kalemeera

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4464303/publications.pdf

Version: 2024-02-01

623188 525886 33 796 14 27 citations g-index h-index papers 36 36 36 950 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Assessing smoking cessation services and pharmacotherapy in Namibia: findings and implications for future policy initiatives. Expert Review of Pharmacoeconomics and Outcomes Research, 2022, 22, 699-710.	0.7	2
2	Antimicrobial resistance among bacteria isolated from urinary tract infections in females in Namibia, 2016–2017. Antimicrobial Resistance and Infection Control, 2022, 11, 33.	1.5	6
3	Tenofovir disoproxil fumarate associated nephrotoxicity: a retrospective cohort study at two referral hospitals in Namibia. Pharmacoepidemiology and Drug Safety, 2021, 30, 189-200.	0.9	6
4	Antibiotics' susceptibility patterns of bacterial isolates causing lower respiratory tract infections in ICU patients at referral hospitals in Namibia. Hospital Practice (1995), 2021, 49, 356-363.	0.5	2
5	Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications. BioMed Research International, 2021, 2021, 1-16.	0.9	7
6	Evaluation of Namibia's antiretroviral therapy guidelines' recommendations for switching from first-line to second-line, using predictors of first-line treatment failure: an exploratory study. Expert Review of Anti-Infective Therapy, 2021, , 1-7.	2.0	0
7	Challenges and Innovations Brought about by the COVID-19 Pandemic Regarding Medical and Pharmacy Education Especially in Africa and Implications for the Future. Healthcare (Switzerland), 2021, 9, 1722.	1.0	33
8	Effect of TDF-containing regimens on creatinine clearance in HIV patients in Namibia with a baseline CrCl <60ml/min; findings and implications. Hospital Practice (1995), 2020, 48, 35-40.	0.5	2
9	Utility of medicines information leaflets in hypertensive care in a setting with low health literacy: A cross-sectional study. Medicine Access Point of Care, 2020, 4, 239920262091003.	1.0	O
10	Response to the Novel Corona Virus (COVID-19) Pandemic Across Africa: Successes, Challenges, and Implications for the Future. Frontiers in Pharmacology, 2020, 11, 1205.	1.6	143
11	Fixed dose drug combinations $\hat{a}\in$ are they pharmacoeconomically sound? Findings and implications especially for lower- and middle-income countries. Expert Review of Pharmacoeconomics and Outcomes Research, 2020, 20, 1-26.	0.7	47
12	Ongoing and planned activities to improve the management of patients with Type 1 diabetes across Africa; implications for the future. Hospital Practice (1995), 2020, 48, 51-67.	0.5	33
13	Review of Ongoing Activities and Challenges to Improve the Care of Patients With Type 2 Diabetes Across Africa and the Implications for the Future. Frontiers in Pharmacology, 2020, 11, 108.	1.6	79
14	Pharmacotherapeutic interventions for bipolar disorder type II: addressing multiple symptoms and approaches with a particular emphasis on strategies in lower and middle-income countries. Expert Opinion on Pharmacotherapy, 2019, 20, 2237-2255.	0.9	38
15	Quality of DOTS Adherence Counselling among Hospitalized Tuberculosis Patients. Journal of Tuberculosis Research, 2019, 07, 77-94.	0.1	O
16	Liver enzyme elevations in a cohort of HIV/AIDS patients on first-line antiretroviral therapy in Namibia: Findings and implications. Alexandria Journal of Medicine, 2018, 54, 49-56.	0.4	15
17	Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets. Frontiers in Public Health, 2018, 6, 328.	1.3	102
18	An analysis of policies for cotrimoxazole, amoxicillin and azithromycin use in Namibia's public sector: Findings and therapeutic implications. International Journal of Clinical Practice, 2017, 71, e12918.	0.8	23

#	Article	IF	CITATIONS
19	Outcome of the second Medicines Utilisation Research in Africa Group meeting to promote sustainable and appropriate medicine use in Africa. Expert Review of Pharmacoeconomics and Outcomes Research, 2017, 17, 149-152.	0.7	10
20	Compliance to guidelines for the prescribing of antibiotics in acute infections at Namibia's national referral hospital: a pilot study and the implications. Expert Review of Anti-Infective Therapy, 2017, 15, 713-721.	2.0	62
21	Evidence on the cost-effectiveness of lifelong antiretroviral therapy for prevention of mother-to-child transmission of HIV: implications for resource-limited countries in sub-Saharan Africa. Expert Review of Pharmacoeconomics and Outcomes Research, 2017, 17, 459-467.	0.7	6
22	Assessing Adherence to Antihypertensive Therapy in Primary Health Care in Namibia: Findings and Implications. Cardiovascular Drugs and Therapy, 2017, 31, 565-578.	1.3	68
23	The Potential Effect of Using the Cockcroft-Gault Method on Tenofovir-Associated Renal Impairment Reports and on Clinical Decisions Regarding Tenofovir Use in Individual Patients: Implications for the Future. Journal of Ancient Diseases & Preventive Remedies, 2017, 5, .	0.2	3
24	Effect of changing from first- to second-line antiretroviral therapy on renal function: a retrospective study based on data from a single health facility in Namibia. Expert Review of Anti-Infective Therapy, 2016, 14, 777-783.	2.0	14
25	Assessment of the nevirapine safety signal using data from the national antiretroviral dispensing database: a retrospective study. Journal of Pharmaceutical Policy and Practice, 2016, 9, 5.	1.1	0
26	Tenofovir substitution in Namibia based on an analysis of the antiretroviral dispensing database. Journal of Pharmaceutical Policy and Practice, 2015, 8, 14.	1.1	3
27	Implementing clinical pharmacy within undergraduate teaching in Namibia. International Journal of Clinical Pharmacy, 2015, 37, 427-429.	1.0	7
28	Antimicrobial sensitivity patterns of cerebrospinal fluid (CSF) isolates in Namibia: implications for empirical antibiotic treatment of meningitis. Journal of Pharmaceutical Policy and Practice, 2013, 6, 4.	1.1	27
29	Records linkage of electronic databases for the assessment of adverse effects of antiretroviral therapy in subâ€5aharan Africa. Pharmacoepidemiology and Drug Safety, 2012, 21, 407-414.	0.9	8
30	Nevirapine pharmacokinetics when initiated at 200 mg or 400 mg daily in HIV-1 and tuberculosis co-infected Ugandan adults on rifampicin. Journal of Antimicrobial Chemotherapy, 2011, 66, 180-183.	1.3	21
31	Steady-state Pharmacokinetic Comparison of Generic and Branded Formulations of Lamivudine, Stavudine, and Nevirapine in HIV-infected Ugandan Adults. International Journal of Infectious Diseases, 2008, 12, e199.	1.5	0
32	Steady-state pharmacokinetic comparison of generic and branded formulations of stavudine, lamivudine and nevirapine in HIV-infected Ugandan adults. Journal of Antimicrobial Chemotherapy, 2008, 62, 1113-1117.	1.3	10
33	Migration to online pharmacy education in Namibia: Successes, challenges and competence implications. Pharmacy Education, 0, , 174-182.	0.2	1